PDS Biotechnology Corp APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PDS Biotechnology Corp (PDSB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- PDS Biotechnology Corp apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.13M, a 151.34% increase year-over-year.
- PDS Biotechnology Corp apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.16M, a 7.77% decline year-over-year.
- PDS Biotechnology Corp apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $1.16M, a 29.56% decline year-over-year.
- PDS Biotechnology Corp apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.25M, a 29.90% decline year-over-year.
- PDS Biotechnology Corp apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $4.07M, a 842.46% increase from fiscal 2020.
- PDS Biotechnology Corp apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $432.32K, a 86.23% decline from fiscal 2019.
- PDS Biotechnology Corp apic, share-based payment arrangement, increase for cost recognition for fiscal 2019 was $3.14M, a 1145.92% increase from fiscal 2018.
- PDS Biotechnology Corp apic, share-based payment arrangement, increase for cost recognition for fiscal 2018 was $251.95K, a 95.93% decline from fiscal 2017.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.13M 10-Q · filed 2026-08-13 | $2.28M derived: sum of 2 quarters · filed 2026-08-13 | $3.44M derived: sum of 3 quarters · filed 2026-08-13 | $4.69M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $1.16M 10-Q · filed 2026-08-13 | $2.31M derived: sum of 2 quarters · filed 2026-08-13 | $3.56M derived: sum of 3 quarters · filed 2026-08-13 | $4.01M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $1.16M 10-K · filed 2026-03-30 | $2.40M derived: sum of 2 quarters · filed 2026-03-30 | $2.85M derived: sum of 3 quarters · filed 2026-08-13 | $4.11M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-09-30 | $1.25M 10-K · filed 2026-03-30 | $1.69M derived: sum of 2 quarters · filed 2026-08-13 | $2.95M derived: sum of 3 quarters · filed 2026-08-13 | $4.59M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $448.03K 10-Q · filed 2026-08-13 | $1.70M derived: sum of 2 quarters · filed 2026-08-13 | $3.35M derived: sum of 3 quarters · filed 2026-08-13 | $5.12M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $1.25M 10-Q · filed 2026-08-13 | $2.90M derived: sum of 2 quarters · filed 2026-08-13 | $4.68M derived: sum of 3 quarters · filed 2026-08-13 | $6.47M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2024-12-31 | $1.64M 10-K · filed 2026-03-30 | $3.42M derived: sum of 2 quarters · filed 2026-03-30 | $5.22M derived: sum of 3 quarters · filed 2026-03-30 | $6.85M derived: sum of 4 quarters · filed 2026-03-30 | |
| 2024-09-30 | $1.78M 10-K · filed 2026-03-30 | $3.57M derived: sum of 2 quarters · filed 2026-03-30 | $5.20M derived: sum of 3 quarters · filed 2026-03-30 | $6.56M derived: sum of 4 quarters · filed 2026-03-30 | |
| 2024-06-30 | $1.80M 10-K · filed 2026-03-30 | $3.43M derived: sum of 2 quarters · filed 2026-03-30 | $4.78M derived: sum of 3 quarters · filed 2026-03-30 | $6.85M derived: sum of 4 quarters · filed 2026-03-30 | |
| 2024-03-31 | $1.63M 10-K · filed 2026-03-30 | $2.98M derived: sum of 2 quarters · filed 2026-03-30 | $5.06M derived: sum of 3 quarters · filed 2026-03-30 | $7.16M derived: sum of 4 quarters · filed 2026-03-30 | |
| 2023-12-31 | $1.35M 10-K · filed 2025-03-27 | $3.43M derived: sum of 2 quarters · filed 2025-03-27 | $5.53M derived: sum of 3 quarters · filed 2025-03-27 | $7.61M derived: sum of 4 quarters · filed 2025-03-27 | |
| 2023-09-30 | $2.07M 10-K · filed 2025-03-27 | $4.18M derived: sum of 2 quarters · filed 2025-03-27 | $6.26M derived: sum of 3 quarters · filed 2025-03-27 | $7.63M derived: sum of 4 quarters · filed 2025-03-27 | |
| 2023-06-30 | $2.11M 10-K · filed 2025-03-27 | $4.19M derived: sum of 2 quarters · filed 2025-03-27 | $5.56M derived: sum of 3 quarters · filed 2025-03-27 | $6.90M derived: sum of 4 quarters · filed 2025-03-27 | |
| 2023-03-31 | $2.08M 10-K · filed 2025-03-27 | $3.45M derived: sum of 2 quarters · filed 2025-03-27 | $4.80M derived: sum of 3 quarters · filed 2025-03-27 | $6.15M derived: sum of 4 quarters · filed 2025-03-27 | |
| 2022-12-31 | $1.37M 10-K · filed 2024-03-28 | $2.72M derived: sum of 2 quarters · filed 2024-03-28 | $4.07M derived: sum of 3 quarters · filed 2024-03-28 | $5.20M derived: sum of 4 quarters · filed 2024-03-28 | |
| 2022-09-30 | $1.34M 10-K · filed 2024-03-28 | $2.69M derived: sum of 2 quarters · filed 2024-03-28 | $3.82M derived: sum of 3 quarters · filed 2024-03-28 | $5.50M derived: sum of 4 quarters · filed 2024-03-28 | |
| 2022-06-30 | $1.35M 10-K · filed 2024-03-28 | $2.48M derived: sum of 2 quarters · filed 2024-03-28 | $4.15M derived: sum of 3 quarters · filed 2024-03-28 | $5.85M derived: sum of 4 quarters · filed 2024-03-28 | |
| 2022-03-31 | $1.13M 10-K · filed 2024-03-28 | $2.80M derived: sum of 2 quarters · filed 2024-03-28 | $4.50M derived: sum of 3 quarters · filed 2024-03-28 | $4.95M derived: sum of 4 quarters · filed 2024-03-28 | |
| 2021-12-31 | $1.67M 10-K · filed 2023-03-28 | $3.38M derived: sum of 2 quarters · filed 2023-03-28 | $3.82M derived: sum of 3 quarters · filed 2023-03-28 | $4.07M 10-K · filed 2022-03-31 | |
| 2021-09-30 | $1.70M 10-K · filed 2023-03-28 | $2.14M derived: sum of 2 quarters · filed 2023-03-28 | $2.40M 10-Q · filed 2021-11-10 | $2.53M derived: sum of 4 quarters · filed 2023-03-28 | |
| 2021-06-30 | $441.60K 10-K · filed 2023-03-28 | $699.22K 10-Q · filed 2021-08-12 | $830.64K derived: sum of 3 quarters · filed 2023-03-28 | $960.43K derived: sum of 4 quarters · filed 2023-03-28 | |
| 2021-03-31 | $257.62K 10-K · filed 2023-03-28 | $389.05K derived: sum of 2 quarters · filed 2023-03-28 | $518.84K derived: sum of 3 quarters · filed 2023-03-28 | $564.95K derived: sum of 4 quarters · filed 2023-03-28 | |
| 2020-12-31 | $131.42K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $261.21K derived: sum of 2 quarters · filed 2022-03-31 | $307.33K derived: sum of 3 quarters · filed 2022-03-31 | $432.32K 10-K · filed 2022-03-31 | |
| 2020-09-30 | $129.79K 10-Q · filed 2021-11-10 | $175.91K derived: sum of 2 quarters · filed 2021-11-10 | $300.90K 10-Q · filed 2021-11-10 | $546.29K derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $46.11K 10-Q · filed 2021-08-12 | $171.11K 10-Q · filed 2021-08-12 | $416.50K derived: sum of 3 quarters · filed 2021-08-12 | $536.71K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $124.99K 10-Q · filed 2021-05-13 | $370.39K derived: sum of 2 quarters · filed 2021-05-13 | $490.59K derived: sum of 3 quarters · filed 2021-05-13 | $509.17K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $245.40K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $365.60K derived: sum of 2 quarters · filed 2021-03-18 | $384.18K derived: sum of 3 quarters · filed 2021-03-18 | $3.14M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $120.21K 10-Q · filed 2020-11-13 | $138.79K derived: sum of 2 quarters · filed 2020-11-13 | $2.89M 10-Q · filed 2020-11-13 | $3.10M derived: sum of 4 quarters · filed 2020-11-13 | |
| 2019-06-30 | $18.58K 10-Q · filed 2020-08-13 | $2.77M 10-Q · filed 2020-08-13 | $2.98M derived: sum of 3 quarters · filed 2020-08-13 | $3.02M derived: sum of 4 quarters · filed 2020-08-13 | |
| 2019-03-31 | $2.75M 10-Q · filed 2020-05-13 | $2.96M derived: sum of 2 quarters · filed 2020-05-13 | $3.00M derived: sum of 3 quarters · filed 2020-05-13 | $3.00M derived: sum of 4 quarters · filed 2020-05-13 | |
| 2018-12-31 | $202.61K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $244.30K derived: sum of 2 quarters · filed 2020-03-27 | $244.93K derived: sum of 3 quarters · filed 2020-03-27 | $251.95K 10-K · filed 2020-03-27 | $7.47M 10-K · filed 2019-02-21 |
| 2018-09-30 | $41.69K 10-Q · filed 2019-11-07 | $42.32K derived: sum of 2 quarters · filed 2019-11-07 | $49.34K 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $630.00 10-Q · filed 2019-08-01 | $7.64K 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | $7.01K 10-Q · filed 2019-05-14 | ||||
| 2017-12-31 | $6.18M 10-K · filed 2019-02-21 | ||||
| 2016-12-31 | $5.31M 10-K · filed 2018-03-01 | ||||
| 2015-12-31 | $2.90M 10-K · filed 2018-03-01 | ||||
| 2014-12-31 | $1.30M 10-K · filed 2017-03-02 | ||||
| 2013-12-31 | $260.36K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |